Congressional hearing to discuss AI’s role in transforming U.S. healthcare

Congressional hearing to discuss AI’s role in transforming U.S. healthcare
Andrew M. Ibrahim MD, MSc, Chief Clinical Officer at the Viz.ai - Provided photo
0Comments

Congressmen Brett Guthrie and Morgan Griffith have announced a hearing to explore the integration of artificial intelligence (AI) in the U.S. healthcare system. The event, titled “Examining Opportunities to Advance American Health Care through the Use of Artificial Intelligence Technologies,” is scheduled for September 3, 2025, at 10:15 AM ET in the Rayburn House Office Building. It will be open to both the public and press and will also be available via livestream on energycommerce.house.gov.

Guthrie, Chairman of the House Committee on Energy and Commerce, along with Griffith, Chairman of the Subcommittee on Health, emphasized AI’s potential in healthcare. They said that AI could enhance care delivery, strengthen provider-patient relationships, reduce administrative burdens for clinicians, and empower patients.

Andrew M. Ibrahim, Chief Clinical Officer at Viz.ai, is set to testify at the hearing. Viz.ai’s platform is an example of AI’s practical application in healthcare. The platform is FDA-cleared and CMS-reimbursed and is currently used in over 1,800 hospitals across the United States. According to Ibrahim, “AI in healthcare is not hype.” He noted that their technology has been effective in reducing treatment times for conditions like stroke and pulmonary embolism.

Ibrahim also highlighted that Congress can play a role in accelerating AI adoption by creating efficient FDA pathways and ensuring data interoperability. This would help ensure that all patients benefit from AI advancements.

For further information regarding this hearing or press inquiries, individuals can contact Annabelle Huffman or Katie West via email.

Information from this article can be found here.



Related

UCSF neurosurgeon criticizes effectiveness of the 340B Drug Pricing Program

UCSF neurosurgeon criticizes effectiveness of the 340B Drug Pricing Program

Anthony DiGiorgio, a neurosurgeon at the University of California, San Francisco, has expressed concerns about the 340B Drug Pricing Program.

UCSF neurosurgeon criticizes effectiveness of the 340B Drug Pricing Program

UCSF neurosurgeon calls for reform of hospital use of drug discount program

Anthony DiGiorgio, a neurosurgeon at the University of California, San Francisco, has expressed concerns regarding the 340B drug discount program.

University of San Francisco continues to mandate “COVID” mRNA injections

University of San Francisco continues to mandate “COVID” mRNA injections

University of San Francisco in San Francisco, California, still requires students to have “COVID” mRNA injections to attend their classes.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from San Francisco Sun.